Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Breast. 2018 Dec;42:1-2. doi: 10.1016/j.breast.2018.08.096. Epub 2018 Aug 9.
Ribociclib is a CDK4-6 inhibitor recently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first-line treatment for metastatic breast cancer (MBC). The pivotal trial showed a significant improvement in progression-free survival when compared to endocrine therapy alone. However, having a challenging toxicity profile in comparison with exclusive endocrine therapy, safety may be a concern when combined to radiotherapy (RT) with palliative approach. There are no available published data regarding the combination of ribociclib and palliative RT. We reported our preliminary experience on the first five patients treated at the Radiation Oncology Unit of the Florence University (Florence, Italy) giving palliative RT concomitant to ribociclib plus letrozole as first-line treatment for MBC.
瑞博西利是一种 CDK4-6 抑制剂，最近被美国食品和药物管理局（FDA）和欧洲药品管理局（EMA）批准作为转移性乳腺癌（MBC）的一线治疗药物。关键性试验表明，与单独内分泌治疗相比，无进展生存期有显著改善。然而，与单独内分泌治疗相比，瑞博西利具有挑战性的毒性特征，当与姑息性放疗（RT）联合应用时，安全性可能是一个问题。目前尚无关于瑞博西利联合姑息性 RT 的可用数据。我们报告了在意大利佛罗伦萨大学放射肿瘤学系（佛罗伦萨）治疗的前五例患者的初步经验，这些患者接受了瑞博西利联合来曲唑作为 MBC 一线治疗的同时给予姑息性 RT。
